Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents

Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Amblard, M.A., Costantini, E., Hayek, G., Ricaud, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS. 2022
Materias:
Article Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499740/
https://www.ncbi.nlm.nih.gov/pubmed/36155145
http://dx.doi.org/10.1016/j.jfo.2022.09.004
_version_ 1784795064921227264
author Amblard, M.A.
Costantini, E.
Hayek, G.
Ricaud, X.
author_facet Amblard, M.A.
Costantini, E.
Hayek, G.
Ricaud, X.
author_sort Amblard, M.A.
collection PubMed
description Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO).
format Online
Article
Text
id pubmed-9499740
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-94997402022-09-23 Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents Amblard, M.A. Costantini, E. Hayek, G. Ricaud, X. J Fr Ophtalmol Article Original Coronavirus disease 19 (COVID-19) was first observed in Wuhan, China. The disease is caused by a virus (SARS-CoV-2), which spread around the world within a matter of weeks, leading to a large number of deaths. While the health crisis was managed on the ground, the scientific community focused on finding a means to stop it. Vaccine candidates such as the mRNA vaccines (Pfizer BTN162b2 and Moderna mRNA-1273), started to emerge. As these treatments came on the market recently, there is still concern about potential side effects, among them, Herpes Zoster Ophthalmicus (HZO). Published by Elsevier Masson SAS. 2022-11 2022-09-23 /pmc/articles/PMC9499740/ /pubmed/36155145 http://dx.doi.org/10.1016/j.jfo.2022.09.004 Text en © 2022 Published by Elsevier Masson SAS. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article Original
Amblard, M.A.
Costantini, E.
Hayek, G.
Ricaud, X.
Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title_full Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title_fullStr Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title_full_unstemmed Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title_short Zona ophtalmique après vaccination par Pfizer BNT162b2 et Moderna mRNA-1273 chez deux patients jeunes et immunocompétents
title_sort zona ophtalmique après vaccination par pfizer bnt162b2 et moderna mrna-1273 chez deux patients jeunes et immunocompétents
topic Article Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499740/
https://www.ncbi.nlm.nih.gov/pubmed/36155145
http://dx.doi.org/10.1016/j.jfo.2022.09.004
work_keys_str_mv AT amblardma zonaophtalmiqueapresvaccinationparpfizerbnt162b2etmodernamrna1273chezdeuxpatientsjeunesetimmunocompetents
AT costantinie zonaophtalmiqueapresvaccinationparpfizerbnt162b2etmodernamrna1273chezdeuxpatientsjeunesetimmunocompetents
AT hayekg zonaophtalmiqueapresvaccinationparpfizerbnt162b2etmodernamrna1273chezdeuxpatientsjeunesetimmunocompetents
AT ricaudx zonaophtalmiqueapresvaccinationparpfizerbnt162b2etmodernamrna1273chezdeuxpatientsjeunesetimmunocompetents

Ejemplares similares